Affection Animal Pharmaceuticals key facts
as of Oct 2026- Developer of pet vaccines intended to enhance pet health condition.
- Affection Animal Pharmaceuticals is valued at approximately $363.2M as of Oct 2026 (last reported valuation).
- It has raised $43.7M; the latest was Later Stage VC ($13.7M) in Jan 2025.
- Notable investors include SND Ventures Group, Suzhou Guofa Venture Capital, GSR United Capital, New Alliance Capital, Haihe River Industry Fund — 12 tracked in total.
- Status: Privately Held (backing).
Affection Animal Pharmaceuticals's last reported valuation, Sep 2022. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Affection Animal Pharmaceuticals: the Monday email on marks, rounds and moves
Affection Animal Pharmaceuticals funding rounds
No funding rounds for Affection Animal Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Affection Animal Pharmaceuticals
12+Membership and data by Private Market View
Affection Animal Pharmaceuticals valuation
Affection Animal Pharmaceuticals's last reported valuation was $363 million in Sep 2022. No priced round, secondary trade or fund mark has surfaced since.
Affection Animal Pharmaceuticals investors
12 investors are on record for Affection Animal Pharmaceuticals, including SND Ventures Group, Suzhou Guofa Venture Capital, GSR United Capital and New Alliance Capital.
About Affection Animal Pharmaceuticals
Developer of pet vaccines intended to enhance pet health condition. The company's products include veterinary biological products and veterinary chemical drugs, enabling pet families to protect pets from serious diseases.
- Sector
- Business Products and Services (B2B)
- HQ
- Suzhou, China
- Founded
- 2018
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.